We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+7.2%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$642M
AUM Growth
-$79.9M
Cap. Flow
-$91.9M
Cap. Flow %
-14.33%
Top 10 Hldgs %
61.3%
Holding
48
New
10
Increased
10
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$27.6M
2
TGTX icon
TG Therapeutics
TGTX
+$22.3M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$21.1M
4
UTHR icon
United Therapeutics
UTHR
+$16.1M
5
EXEL icon
Exelixis
EXEL
+$14.4M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$35.2M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$34.8M
3
NVCR icon
NovoCure
NVCR
+$22.3M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$13.7M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
1
BioCryst Pharmaceuticals
BCRX
$2.28B
$60.9M 9.49%
7,978,275
+500,000
+7% +$3.36M
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$52.5M 8.19%
917,767
+159,767
+21% +$7.85M
LRMR icon
3
Larimar Therapeutics
LRMR
$397M
$39.6M 6.18%
282,615
-9,052
-3% -$1.1M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$1.82B
$39.3M 6.13%
3,496,340
+10,595
+0.3% +$150K
UTHR icon
5
United Therapeutics
UTHR
$25.8B
$38.4M 5.98%
300,000
+130,361
+77% +$16.1M
KURA icon
6
Kura Oncology
KURA
$800M
$37.1M 5.78%
2,119,106
-508,004
-19% -$9.74M
EXEL icon
7
Exelixis
EXEL
$13.3B
$36.8M 5.73%
2,075,000
+740,207
+55% +$14.4M
PTCT icon
8
PTC Therapeutics
PTCT
$5.64B
$33.7M 5.26%
717,458
-851,042
-54% -$35.2M
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
$28.5M 4.45%
+1,606,100
New +$27.6M
VYGR icon
10
Voyager Therapeutics
VYGR
$183M
$26.5M 4.13%
1,400,000
+669,990
+92% +$12.9M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$27.5B
$26.3M 4.09%
300,000
+39,900
+15% +$4.01M
SVRA icon
12
Savara
SVRA
$1.12B
$25M 3.9%
2,243,084
+1,068,543
+91% +$12.3M
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$4.43B
$24.8M 3.87%
1,196,098
-803,902
-40% -$12.6M
FOMX
14
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$23.1M 3.6%
4,030,268
-751,440
-16% -$4.3M
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$22.9M 3.57%
1,647,753
+387,753
+31% +$5.77M
CYTK icon
16
Cytokinetics
CYTK
$10.5B
$21.5M 3.35%
2,179,688
+735,207
+51% +$5.9M
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$21.4M 3.34%
393,147
-106,853
-21% -$7.31M
ENTA icon
18
Enanta Pharmaceuticals
ENTA
$366M
$18M 2.8%
+210,400
New +$21.1M
YARW
19
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$12.8M 2%
+362
New +$11.2M
TGTX icon
20
TG Therapeutics
TGTX
$7.96B
$10.9M 1.7%
+1,950,000
New +$22.3M
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.79B
$10.1M 1.58%
982,449
-491,160
-33% -$4.23M
ARGX icon
22
argenx
ARGX
$53.4B
$9.79M 1.53%
+129,060
New +$11.4M
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$10.8B
$8.65M 1.35%
+40,400
New +$10.1M
ITCI
24
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.34M 0.68%
+200,000
New +$4.18M
ZYME icon
25
Zymeworks
ZYME
$1.61B
$3.8M 0.59%
+241,970
New +$3.46M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Great Point Partners held 48 positions worth $642M, down 11% from $722M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Great Point Partners withdrew a net $91.9M in Q3 2018, closing 18 positions and reducing 9 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $34.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Endocyte, Inc. Common Stock worth $28.5M.

  • Great Point Partners's largest Q3 2018 buy was Endocyte, Inc. Common Stock: 1,606,100 shares worth $28.5M.
  • Great Point Partners added most to United Therapeutics in Q3 2018, an estimated $16.1M increase.
  • Great Point Partners's biggest Q3 2018 reduction was PTC Therapeutics, cutting an estimated $35.2M.
  • Great Point Partners fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $34.8M.
  • Great Point Partners's ten largest holdings make up 61% of its $642M portfolio in Q3 2018.
  • Great Point Partners opened 10 new positions and closed 18 in Q3 2018.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $642M.

Based on Great Point Partners's 13F filing for Q3 2018, filed 14 Nov 2018.